Benralizumab attenuates blood and airway eosinophilia in severe asthmatics with inadequate response to anti-IL-5 neutralizing antibodies
M. Mukherjee (Hamilton (ON), Canada), A. Bhalla (Hamilton (ON), Canada), C. Venegas-Garrido (Hamilton (ON), Canada), C. Huang (Hamilton (ON), Canada), K. Radford (Hamilton (ON), Canada), M. Kjarsgaard (Hamilton (ON), Canada), S. Lauks (Hamilton (ON), Canada), K. Son (Hamilton (ON), Canada), N. Lavigne (Hamilton (ON), Canada), R. Sehmi (Hamilton (ON), Canada), P. O'Byrne (Hamilton (ON), Canada), P. Nair (Hamilton (ON), Canada)
Source: International Congress 2022 – Recent advances in biological treatments for asthma
Session: Recent advances in biological treatments for asthma
Session type: Oral Presentation
Number: 3673
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Mukherjee (Hamilton (ON), Canada), A. Bhalla (Hamilton (ON), Canada), C. Venegas-Garrido (Hamilton (ON), Canada), C. Huang (Hamilton (ON), Canada), K. Radford (Hamilton (ON), Canada), M. Kjarsgaard (Hamilton (ON), Canada), S. Lauks (Hamilton (ON), Canada), K. Son (Hamilton (ON), Canada), N. Lavigne (Hamilton (ON), Canada), R. Sehmi (Hamilton (ON), Canada), P. O'Byrne (Hamilton (ON), Canada), P. Nair (Hamilton (ON), Canada). Benralizumab attenuates blood and airway eosinophilia in severe asthmatics with inadequate response to anti-IL-5 neutralizing antibodies. 3673
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|